The Evolving Landscape of Immunotherapy in Advanced Prostate Cancer

• DOI: 10.2217/imt-2019-0019
• Publication Date: 2019-06-04T13:08:51Z
• Authors: Vaibhav G Patel; William K Oh
• Keywords: Immune checkpoint

Prostate cancer exists in a clinical continuum of hormone-sensitive to castration-resistant disease. Despite the use chemotherapy and androgen synthesis inhibitors setting, this remains lethal The advent immune checkpoint blockade has changed outlook for treatment survival several tumors since its first approval 2011; however, benefit prostate (CRPC) is rather limited. Currently, Sipuleucel-T only modality be approved CRPC setting. Such resistance likely due low immunogenicity tumor cells an immunosuppressive microenvironment. In review, we describe early experiences therapeutic vaccines CRPC. We then outline strategies currently being implemented overcome resistance, as well genomic biomarker investigation identify patients that may harbor more immunogenic tumors. At last, preview emerging immunotherapeutic platforms.